Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. JW (Cayman) Therapeutics Co. Ltd
  6. Summary
    2126   KYG5210T1040

JW (CAYMAN) THERAPEUTICS CO. LTD

(2126)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/07/2021 10/08/2021 10/11/2021 10/12/2021 10/15/2021 Date
14.56 13.98 14.5 14.06 14.02 Last
1234087 2873000 1802171 1584175 1219000 Volume
+2.39% -3.98% +3.72% -3.03% -0.28% Change
Estimated financial data (e)
Sales 2021 123 M 19,0 M 19,0 M
Net income 2021 -629 M -97,8 M -97,8 M
Net cash position 2021 1 868 M 290 M 290 M
P/E ratio 2021 -8,25x
Yield 2021 -
Sales 2022 337 M 52,3 M 52,3 M
Net income 2022 -526 M -81,7 M -81,7 M
Net cash position 2022 2 151 M 334 M 334 M
P/E ratio 2022 -7,31x
Yield 2022 -
Capitalization 4 717 M 733 M 733 M
EV / Sales 2021 23,3x
EV / Sales 2022 7,62x
Nbr of Employees 477
Free-Float 57,9%
More Financials
Company
JW Cayman Therapeutics Co Ltd is a China-based company mainly engaged in the clinical and pre-clinical stage cell therapy. The Company is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for... 
More about the company
Ratings of JW (Cayman) Therapeutics Co. Ltd
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about JW (CAYMAN) THERAPEUTICS CO. LTD
10/04JW CAYMAN THERAPEUTICS : Therapeutics Awards 7 Million Share Options, Nearly 5 Million Res..
MT
09/28JW (CAYMAN) THERAPEUTICS : to Start Clinical Trials of Multiple Myeloma Treatment in China
MT
09/27JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
CI
09/26JW CAYMAN THERAPEUTICS : Therapeutics Says Immunotherapy Shows Long-Term Efficacy in Large..
MT
09/26JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel ..
CI
09/06JW CAYMAN THERAPEUTICS : Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel..
AQ
09/03JW CAYMAN THERAPEUTICS : China Approves JW Therapeutics' Immunotherapy for Lymphoma Treatm..
MT
09/03JW Therapeutics Co. Ltd Announces NMPA Approval of Relmacabtagene Autoleucel Injection ..
CI
08/27JW Therapeutics Co. Ltd Reports Unaudited Consolidated Earnings Results for the Six Mon..
CI
08/20JW THERAPEUTICS : Announces Strategic Partnership with MediTrust Health
PR
08/20JW Therapeutics Announces Strategic Partnership with Meditrust Health
CI
07/30JW CAYMAN THERAPEUTICS : Change of company secretary, authorized representative and proces..
PU
07/30JW Therapeutics Co. Ltd. Announces Change of Company Secretary
CI
05/21JW CAYMAN THERAPEUTICS : Syracuse Biopharma Eyes Sale of Nearly 11% Stake in JW Therapeuti..
MT
05/01267,650,120 Ordinary Shares of JW Therapeutics Co. Ltd are subject to a Lock-Up Agreeme..
CI
More news
News in other languages on JW (CAYMAN) THERAPEUTICS CO. LTD
09/03La Chine approuve l'immunothérapie de JW Therapeutics pour le traitement du lymphome
More news
Chart JW (CAYMAN) THERAPEUTICS CO. LTD
Duration : Period :
JW (Cayman) Therapeutics Co. Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JW (CAYMAN) THERAPEUTICS CO. LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 11,60 CNY
Average target price 27,26 CNY
Spread / Average Target 135%
EPS Revisions
Managers and Directors
Yi Ping Li Chairman & Chief Executive Officer
Xin Fu Chief Financial Officer & Senior Vice President
Lapyuen Harry Lam Chief Technology Officer & Executive VP
Chi Shing Li Independent Non-Executive Director
Yiu Leung Cheung Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JW (CAYMAN) THERAPEUTICS CO. LTD-46.79%733
GILEAD SCIENCES, INC.16.08%85 447
WUXI APPTEC CO., LTD.29.45%65 650
BIONTECH SE203.83%60 460
REGENERON PHARMACEUTICALS14.52%57 767
VERTEX PHARMACEUTICALS-23.09%47 190